The pyrrolidinamide antimalarial drug MMV367 rapidly clears blood-stage Plasmodium falciparum in healthy adults with experimental malaria
Science Translational Medicine · 10.06.2026 · 18 (853)
DOI: 10.1126/scitranslmed.aec1863 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Translational Medicine, erschienen am 10.06.2026. Verfasst von Bridget E Barber und 28 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infection and Inflammation, QIMR Berghofer, Brisbane 4006, Australia. Hauptthemen laut MEDLINE: Plasmodium falciparum, Antimalarials, Malaria, Falciparum, Pyrrolidines. Die Arbeit nennt 34 Literaturangaben. Gefördert von: Bill and Melinda Gates Foundation, Medicines for Malaria Venture, GSK.
Abstract (Originalsprache)
Fast-acting antimalarial drugs are needed to address the emergence of artemisinin resistance in the protozoan parasite Plasmodium falciparum, the major cause of severe malaria worldwide. The pyrrolidinamide antimalarial drug MMV367 (GSK3772701) potentially interferes with parasite metabolism mediated by P. falciparum acyl-CoA synthetases 10 and 11. In this volunteer infection study, the antimalarial activity of MMV367 was tested against blood-stage P. falciparum in 12 healthy malaria-naïve adults. The study participants were inoculated with P. falciparum 3D7–infected erythrocytes on day 0 and received a single oral dose of MMV367 at 3 mg ( n = 3), 5 mg ( n = 2), 10 mg ( n = 1), 20 mg ( n = 3), 90 mg ( n = 2), or 1500 mg ( n = 1) on day 8. All participants received artemether-lumefantrine on or before day 24. Maximum MMV367 plasma concentrations occurred 2 to 4 hours postdose, and the elimination half-life was 12.9 to 18 hours. For doses of ≥20 mg, the parasite clearance half-life was 2.2 to 4.3 hours with viable parasites declining more rapidly (elimination half-life of 1.1 to 2.7 hours). A clearance pharmacokinetic/pharmacodynamic model described the relationship between MMV367 concentrations and parasite killing and subsequent clearance of nonviable parasites. Model-derived efficacy parameters included a minimum inhibitory concentration of 6.3 ng/ml (95% CI, 5.2 to 7.8) and a minimum parasiticidal concentration with 90% of maximum effect of 54 ng/ml (95% CI, 43 to 68). No reduction in in vitro susceptibility to MMV367 or genetic determinants of resistance were observed in drug-exposed parasite lines. Most adverse events were attributed to malaria challenge, and none were serious. Higher MMV367 doses were not associated with an increased incidence or severity of adverse events. These findings support further clinical development of MMV367.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Infection and Inflammation, QIMR Berghofer, Brisbane 4006, Australia.
- Infectious Diseases Unit, Royal Brisbane and Women's Hospital, Brisbane 4006, Australia.
- University of the Sunshine Coast Clinical Trials, Brisbane 4101, Australia.
- Medicines for Malaria Venture, 1215 Geneva 15, Switzerland.
- Biostatistics and Data Science Division, George Institute for Global Health School of Population Health, University of New South Wales, Sydney 2031, Australia.
- Kirby Institute, University of New South Wales, Sydney 2052, Australia.
ORCID-Profile: Bridget E Barber, Robin Denhardt-Eriksson, Etienne A Guirou, Nischal Sahai, Indika Leelasena, Susan Mathison, Chris Moller, Ivan Lim, Carla Evangelista, Rebecca Webster, Stacey Llewellyn, Fiona H Amante, Jeremy Gower, David S Khoury, Vandana Thathy, Sunil K Narwal, Tomas Yeo, David A Fidock, Francisco-Javier Gamo, Rachel A Gibson, Laura Sanz, Anthony Cahn, Stephan Chalon
Förderung
- Bill and Melinda Gates Foundation
- Medicines for Malaria Venture
- GSK
- Gates Foundation
- Medicines for Malaria Venture and GSK
Zitieren
APA
Barber, B. E., Denhardt-Eriksson, R., Guirou, E. A., Flynn, J., Sahai, N., Leelasena, I., Mathison, S., Moller, C., Lim, I., Evangelista, C., Webster, R., Potter, A. J., Llewellyn, S., Amante, F. H., Gower, J., Peters, J., Khoury, D. S., Thathy, V., Narwal, S. K., …, & Chalon, S. (2026). The pyrrolidinamide antimalarial drug MMV367 rapidly clears blood-stage Plasmodium falciparum in healthy adults with experimental malaria. Science Translational Medicine, 18(853). https://doi.org/10.1126/scitranslmed.aec1863
Vancouver
Barber BE, Denhardt-Eriksson R, Guirou EA, Flynn J, Sahai N, Leelasena I, et al. The pyrrolidinamide antimalarial drug MMV367 rapidly clears blood-stage Plasmodium falciparum in healthy adults with experimental malaria. Science Translational Medicine. 2026;18(853). doi:10.1126/scitranslmed.aec1863
BibTeX
@article{Barber2026,
author = {Barber, Bridget E and Denhardt-Eriksson, Robin and Guirou, Etienne A and Flynn, Julia and Sahai, Nischal and Leelasena, Indika and Mathison, Susan and Moller, Chris and Lim, Ivan and Evangelista, Carla and Webster, Rebecca and Potter, Adam J and Llewellyn, Stacey and Amante, Fiona H and Gower, Jeremy and Peters, Jenny and Khoury, David S and Thathy, Vandana and Narwal, Sunil K and Yeo, Tomas and Fidock, David A and Marx, Michael W and Gamo, Francisco-Javier and Sharma, Raman and Gibson, Rachel A and Sanz, Laura and Cahn, Anthony and Bestgen, Benoit and Chalon, Stephan},
title = {The pyrrolidinamide antimalarial drug MMV367 rapidly clears blood-stage Plasmodium falciparum in healthy adults with experimental malaria},
journal = {Science Translational Medicine},
year = {2026},
volume = {18},
number = {853},
doi = {10.1126/scitranslmed.aec1863}
}
EUVIMED